MedPath

Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis

Active, not recruiting
Conditions
Pancreatic Adenocarcinoma
Registration Number
NCT06760234
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Brief Summary

This study describes the development and validation of a deep learning prediction model, which extracts deep learning features from preoperative enhanced CT scans and analyzes postoperative pathological specimens of pancreatic cancer patients. The aim is to predict patient prognosis and response to chemotherapy treatment.

Detailed Description

This study retrospectively collected enhanced CT scan data, pathological paraffin blocks, and clinical data from pancreatic cancer patients who underwent surgery at multiple centers between March 2013 and May 2024. The pathological paraffin blocks were stained using immunohistochemistry for prognostic immune microenvironment markers, and patients were classified based on these results. Subsequently, deep learning features were extracted from enhanced CT scans, and a multimodal prediction model was constructed using imaging features and clinical information. The model's performance was evaluated using metrics including area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
247
Inclusion Criteria
  1. Patients with pancreatic cancer, diagnosed through pathology;
  2. Patients underwent surgery and received adjuvant chemotherapy after surgery.
Exclusion Criteria
  1. Missing or inadequate quality of CT,
  2. Incomplete clinical or pathological data.
  3. Multiple primary malignancies;
  4. History of malignancy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Performance of deep learning modelBaseline treatment

The model's performance was evaluated using metrics including area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

the Second Affiliated Hospital Zhejiang University School of Medicine

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath